Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M101,683Revenue $M16,385Net Margin (%)16.9Z-Score5.8
Enterprise Value $M102,188EPS $1.5Operating Margin %17.1F-Score5
P/E(ttm))37.7Cash Flow Per Share $2.8Pre-tax Margin (%)20.6Higher ROA y-yN
Price/Book6.710-y EBITDA Growth Rate %0.8Quick Ratio1.6Cash flow > EarningsY
Price/Sales6.45-y EBITDA Growth Rate %-13.5Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow11.7y-y EBITDA Growth Rate %14.6ROA % (ttm)7.7Higher Current Ratio y-yY
Dividend Yield %2.4Insider Buy (3m)0ROE % (ttm)17.9Less Shares Outstanding y-yN
Payout Ratio %88.0Shares Outstanding M1,659ROI % (ttm)5.7Gross Margin Increase y-yY

Gurus Latest Trades with BMY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYVanguard Health Care Fund 2014-09-30 Add0.3%$47.86 - $51.96
($49.97)
$ 61.323%Add 6.31%38,480,761
BMYRay Dalio 2014-09-30 Buy $47.86 - $51.96
($49.97)
$ 61.323%New holding, 10228 sh.10,228
BMYJoel Greenblatt 2014-09-30 Sold Out -0.05%$47.86 - $51.96
($49.97)
$ 61.323%Sold Out0
BMYVanguard Health Care Fund 2014-06-30 Add0.86%$46.59 - $52.19
($49.29)
$ 61.324%Add 22.96%36,197,961
BMYJoel Greenblatt 2014-06-30 Buy 0.05%$46.59 - $52.19
($49.29)
$ 61.324%New holding, 89363 sh.89,363
BMYRay Dalio 2014-06-30 Sold Out $46.59 - $52.19
($49.29)
$ 61.324%Sold Out0
BMYKen Fisher 2014-06-30 Add$46.59 - $52.19
($49.29)
$ 61.324%Add 216.1%49,732
BMYRonald Muhlenkamp 2014-03-31 Buy 1.9%$48.54 - $56.61
($53.23)
$ 61.315%New holding, 212015 sh.212,015
BMYVanguard Health Care Fund 2014-03-31 Add0.73%$48.54 - $56.61
($53.21)
$ 61.315%Add 20.35%29,437,761
BMYRay Dalio 2014-03-31 Buy $48.54 - $56.61
($53.23)
$ 61.315%New holding, 4428 sh.4,428
BMYGeorge Soros 2014-03-31 Sold Out -0.05%$48.54 - $56.61
($53.23)
$ 61.315%Sold Out0
BMYJoel Greenblatt 2014-03-31 Sold Out -0.02%$48.54 - $56.61
($53.23)
$ 61.315%Sold Out0
BMYJoel Greenblatt 2013-12-31 Buy 0.02%$46.41 - $53.84
($50.96)
$ 61.320%New holding, 11679 sh.11,679
BMYVanguard Health Care Fund 2013-09-30 Add0.64%$41.32 - $47.53
($43.84)
$ 61.340%Add 20.26%24,459,861
BMYIrving Kahn 2013-09-30 Reduce-0.19%$41.32 - $47.53
($43.84)
$ 61.340%Reduce -48.95%28,300
BMYJean-Marie Eveillard 2013-09-30 Reduce-0.01%$41.32 - $47.53
($43.84)
$ 61.340%Reduce -75.17%16,520
BMYVanguard Health Care Fund 2013-06-30 Add0.39%$39.68 - $47.68
($43.41)
$ 61.341%Add 13.32%20,338,461
BMYGeorge Soros 2013-06-30 Buy 0.05%$39.68 - $47.68
($43.41)
$ 61.341%New holding, 100000 sh.100,000
BMYJean-Marie Eveillard 2013-06-30 Add0.01%$39.68 - $47.68
($43.41)
$ 61.341%Add 302.66%66,520
BMYIrving Kahn 2013-06-30 Reduce-2.17%$39.68 - $47.68
($43.41)
$ 61.341%Reduce -86.62%55,433
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMY Ray Dalio 2014-09-3010,22800New Buy
BMY Dodge & Cox 2014-09-3090,4280.010+14.58%
BMY Vanguard Health Care Fund 2014-09-3038,480,7612.325+6.31%
BMY Mario Gabelli 2014-09-30700,2550.040.19+3.79%
BMY Brian Rogers 2014-09-306,264,8000.381.2+3.3%
BMY Ken Fisher 2014-09-3051,20100.01+2.95%
BMY Irving Kahn 2014-09-3027,65000.23
BMY Jean-Marie Eveillard 2014-09-3014,49200
BMY Ronald Muhlenkamp 2014-09-30212,4850.012-0.13%
BMY Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ANDREOTTI LAMBERTOCEO 2014-12-05Sell75,000$60.311.64view
ANDREOTTI LAMBERTOCEO 2014-11-05Sell75,000$57.796.07view
ANDREOTTI LAMBERTOCEO 2014-10-24Sell50,000$5315.66view
CORNELIUS JAMES MDirector 2014-10-15Sell100,000$48.9225.31view
ANDREOTTI LAMBERTOCEO 2014-10-06Sell50,000$50.9920.22view
Cuss Francis MEVP & CSO 2014-09-16Sell63,667$50.7720.74view
Caforio GiovanniCOO 2014-09-15Sell26,691$49.8722.92view
Caldarella Joseph CSVP & Controller 2014-09-10Sell7,415$51.0320.13view
ANDREOTTI LAMBERTOCEO 2014-09-08Sell50,000$51.0520.08view
von Autenried PaulSVP, Enterp. Services & CIO 2014-08-19Sell20,000$49.8922.87view

Press Releases about BMY :

    Quarterly/Annual Reports about BMY:

    News about BMY:

    Articles On GuruFocus.com
    I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
    A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb Nov 24 2014 
    Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
    A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
    Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, Bristol-Myers Squibb Company Oct 19 2014 
    The Six Types of Winning Stocks Oct 17 2014 
    Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model Aug 29 2014 
    Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
    UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
    Pharma Sector Stocks To Consider For Sustained Returns Jun 25 2014 

    More From Our Partners
    Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day Dec 19 2014 - ZACKS

    More From Other Websites
    Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 Dec 17 2014
    Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 Dec 17 2014
    Jim Cramer: These Charts Prove It's Oil-and-Gas vs. Everything Else Dec 16 2014
    Celgene's Abraxane Succeeds In Early Breast Cancer Dec 11 2014
    Gilead Is Growing Fast And Its Stock Is Cheap Dec 11 2014
    Merck's Keytruda Might Treat Virulent Breast Cancer Dec 10 2014
    Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical... Dec 10 2014
    Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical... Dec 10 2014
    Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical... Dec 10 2014
    ONO PHARMACEUTICAL, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical... Dec 10 2014
    Bristol-Myers Squibb Announces Dividend Dec 09 2014
    Bristol-Myers Squibb Announces Dividend Dec 09 2014
    US sues Deutsche in $190m taxes claim Dec 08 2014
    Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data Dec 08 2014
    Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex... Dec 08 2014
    Two Cancer Drugs for Hodgkin Lymphoma Shown Effective Dec 08 2014
    What’s News: Business & Finance Dec 08 2014
    Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex... Dec 08 2014
    Asia Corporate Watch Dec 07 2014
    Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or... Dec 06 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK